Merrimack Pharmaceuticals Inc  

(Public, NASDAQ:MACK)   Watch this stock  
Find more results for MACK
4.74
-0.03 (-0.63%)
Aug 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.62 - 4.88
52 week 4.62 - 11.00
Open 4.74
Vol / Avg. 2.17M/2.04M
Mkt cap 608.75M
P/E     -
Div/yield     -
EPS -1.53
Shares 129.24M
Beta 1.99
Inst. own 68%
Nov 7, 2016
Q3 2016 Merrimack Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 4, 2016
Q2 2016 Merrimack Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2016
Q2 2016 Merrimack Pharmaceuticals Inc Earnings Release
Jun 14, 2016
Merrimack Pharmaceuticals Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -151.30% -165.57%
Operating margin -88.68% -145.16%
EBITD margin - -139.00%
Return on average assets -119.20% -75.14%
Return on average equity - -
Employees 426 -
CDP Score - -

Address

1 Kendall Sq Ste B7201
CAMBRIDGE, MA 02139-1670
United States - Map
+1-617-4411000 (Phone)
+1-617-4911386 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Officers and directors

Gary L. Crocker Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Robert J. Mulroy President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Yasir B Al-Wakeel Chief Financial Officer and Head - Corporate Development
Age: 34
Bio & Compensation  - Reuters
William M. McClements Senior Vice President - Corporate Operations
Age: 51
Bio & Compensation  - Reuters
Edward J. Stewart Senior Vice President and President, Merrimack Healthcare Solutions, Head of Commercial
Age: 44
Bio & Compensation  - Reuters
William A. Sullivan Principal Accounting Officer
Age: 43
Bio & Compensation  - Reuters
Peter N. Laivins Head of Development
Age: 56
Bio & Compensation  - Reuters
Birgit M. Schoeberl Ph.D. Head of Discovery
Age: 42
Bio & Compensation  - Reuters
John M. Dineen Director
Bio & Compensation  - Reuters
Ulrik B. Nielsen Ph.D. Director
Age: 42
Bio & Compensation  - Reuters